{"protocolSection": {"identificationModule": {"nctId": "NCT01068717", "orgStudyIdInfo": {"id": "CV181-118"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants", "officialTitle": "Bioequivalence Study of the Fixed Dose Combination of 2.5 mg Saxagliptin and 500 mg Metformin Tablet Relative to a 2.5 mg Saxagliptin (Onglyza) Tablet and a 500 mg Metformin (Glucophage Marketed in Canada by Sanofi-Aventis) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States"}, "statusModule": {"statusVerifiedDate": "2015-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-03"}, "primaryCompletionDateStruct": {"date": "2010-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-02-12", "studyFirstSubmitQcDate": "2010-02-12", "studyFirstPostDateStruct": {"date": "2010-02-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-08-10", "resultsFirstSubmitQcDate": "2011-09-15", "resultsFirstPostDateStruct": {"date": "2011-10-21", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-04-22", "lastUpdatePostDateStruct": {"date": "2015-05-12", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "To demonstrate the bioequivalence of a 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) tablet to that of 2.5-mg saxagliptin (Onglyza) and 500-mg metformin (Glucophage, marketed in Canada by Sanofi-Aventis) tablets coadministered to healthy participants in the fasted and fed states."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 27, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)", "type": "OTHER", "description": "Single oral doses of saxagliptin, 2.5 mg, and metformin, 500 mg, administered together as tablets in the fasted state", "interventionNames": ["Drug: Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)"]}, {"label": "Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fasted state)", "type": "OTHER", "description": "Single oral dose of a 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) tablet administered in the fasted state", "interventionNames": ["Drug: Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)"]}, {"label": "Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)", "type": "OTHER", "description": "Single oral doses of saxagliptin, 2.5 mg, and metformin, 500 mg, administered together as tablets in the fed state", "interventionNames": ["Drug: Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)"]}, {"label": "Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fed state)", "type": "OTHER", "description": "Single oral dose of saxagliptin, 2.5 mg/metformin, 500 mg, FDC tablet administered in the fed state", "interventionNames": ["Drug: Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)"]}], "interventions": [{"type": "DRUG", "name": "Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)", "description": "Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week", "armGroupLabels": ["Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)"], "otherNames": ["Onglyza\u2122", "Glucophage\u2122"]}, {"type": "DRUG", "name": "Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)", "description": "Tablets, oral, 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC), once daily, 1 week", "armGroupLabels": ["Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fasted state)"]}, {"type": "DRUG", "name": "Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)", "description": "Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week", "armGroupLabels": ["Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)"], "otherNames": ["Onglyza\u2122", "Glucophage\u2122"]}, {"type": "DRUG", "name": "Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)", "description": "Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin FDC, once daily, 1 week", "armGroupLabels": ["Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fed state)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Observed Maximum Plasma Concentration (Cmax) of Saxagliptin, Tablets and Fixed-dose Combination (FDC), Administered to Participants in the Fasted and Fed States", "timeFrame": "Days 1, 2, and 3 of Periods 1, 2, 3, and 4"}, {"measure": "Observed Cmax of Metformin, Tablets and FDC, Administered to Participants in the Fasted and Fed States", "timeFrame": "Days 1, 2, and 3 of Periods 1, 2, 3, and 4"}, {"measure": "Terminal Half-life (t1/2) of Saxagliptin and Metformin, Tablets and FDC, Administered to Participants in the Fasted and Fed States", "timeFrame": "Days 1, 2, and 3 of Periods 1, 2, 3, and 4"}, {"measure": "Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUC[0-t]) for Saxagliptin, Tablets and FDC, Given in the Fasted and Fed States", "timeFrame": "Days 1, 2, and 3 of Periods 1, 2, 3, and 4"}, {"measure": "AUC[0-t] for Metformin, Tablets and FDC, Given in the Fasted and Fed States", "timeFrame": "Days 1, 2, and 3 of Periods 1, 2, 3, and 4"}, {"measure": "AUC From Time 0 Extrapolated to Infinity (AUC[0-inf]) for Saxagliptin, Tablets and FDC, Given in the Fasted and Fed States", "timeFrame": "Days 1, 2, and 3 of Periods 1, 2, 3, and 4"}, {"measure": "AUC[0-inf] for Metformin, Tablets and FDC, Administered in the Fasted and Fed States", "timeFrame": "Days 1, 2, and 3 of Periods 1, 2, 3, and 4"}, {"measure": "Time to Achieve the Observed Maximum Plasma Concentration (Tmax) for Saxagliptin and Metformin, Tablets and FDC, Administered to Participants in the Fasted and Fed States", "timeFrame": "Days 1, 2, and 3 of Periods 1, 2, 3, and 4"}], "secondaryOutcomes": [{"measure": "Number of Participants With Death as Outcome, Serious Adverse Events, and Adverse Events (AEs) Leading to Discontinuation", "description": "An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.", "timeFrame": "Continuously over Days 1 to 3 of treatment Periods 1, 2, 3, and 4"}, {"measure": "Number of Participants With Clinically Significant Abnormalities in Hematology, Serum Chemistry, and Urinalysis Laboratory Test Results", "description": "Clinically significant was determined by the investigator. Hematology tests included hemoglobin, hematocrit, red blood cell count, total leukocyte count (including differential), and platelet count. Serum chemistry tests included aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, lactate dehydrogenase, creatinine, blood urea nitrogen, uric acid, fasting glucose, total protein, albumin, sodium, potassium, chloride, calcium, phosphorus, and creatine kinase. Urinalysis included protein, glucose, blood, leukocyte esterase, specific gravity, and pH.", "timeFrame": "At screening visit, at Day -1 of Periods 1 through 4, and at discharge"}, {"measure": "Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Results", "description": "Clinically significant was determined by the investigator. ECGs were recorded after participants had been supine for at least 5 minutes.", "timeFrame": "At screening visit, Day -1 of Period 1, and at study discharge"}, {"measure": "Number of Participants With Clinically Significant Abnormalities in Body Temperature, Blood Pressure, or Heart Rate", "description": "Clinically significant was determined by the investigator. Blood pressure and heart rate were measured after the participant had been seated quietly for at least 5 minutes.", "timeFrame": "At screening visit, prior to dosing on Day 1 of Periods 1 through 4, and at study discharge."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Men and women, aged 18 to 55 years, inclusive\n* Healthy participants as determined by a lack of clinically significant deviation from normal in medical history, physical examination, electrocardiograms, and clinical laboratory determinations\n* Body Mass Index of 18 to 32 kg/m\\^2, inclusive\n\nExclusion Criteria:\n\n* Any significant acute or chronic medical illness\n* Current or recent (within 3 months) gastrointestinal disease\n* Any major surgery within 4 weeks of study drug administration\n* History of allergy to DPP-4 inhibitors or related compounds\n* History of allergy or intolerance to metformin or other similar acting agents\n* Previous exposure to saxagliptin\n* Exposure to metformin within 3 months pervious to study drug administration\n* Estimated creatinine clearance of \\<80 mL/min using the Cockcroft Gault formula", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Ppd Development, Lp", "city": "Austin", "state": "Texas", "zip": "78744", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 27 participants were enrolled and randomly assigned to 1 of 4 treatment sequences: ADBC, BACD, CBDA, or DCAB. One participant withdrew from the study on Day -1 of Period 2 due to a family emergency and returned for early termination assessments on Day 4 of Period 2. She did not receive study drug in Period 2.", "groups": [{"id": "FG000", "title": "Treatment Schedule ADBC", "description": "(Treatment A) A single oral dose of saxagliptin, 2.5-mg and metformin 500-mg tablets administered together in the fasted state, followed by a 7-day (minimum) washout period. Then, (Treatment D) a single oral dose of 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) in the fasted state, followed by a 7-day (minimum) washout period. Then, (Treatment B) a single oral dose of 2.5-mg saxagliptin/500-mg metformin FDC in the fasted state, followed by a 7-day (minimum) washout period. Then, (Treatment C) a single oral dose of saxagliptin, 2.5-mg and metformin 500-mg tablets administered together in the fed state."}, {"id": "FG001", "title": "Treatment Schedule BACD", "description": "(Treatment B) A single oral dose of 2.5-mg saxagliptin/500-mg metformin FDC in the fasted state, followed by a 7-day (minimum) washout period. Then, (Treatment A) a single oral dose of saxagliptin 2.5-mg and metformin 500-mg tablets administered together in the fasted state, followed by a 7-day (minimum) washout period. Then, (Treatment C) a single oral dose of saxagliptin, 2.5-mg and metformin 500-mg tablets administered together in the fed state. Then, (Treatment D) a single oral dose of 2.5-mg saxagliptin/500-mg metformin FDC administered in the fasted state."}, {"id": "FG002", "title": "Treatment Schedule CBDA", "description": "(Treatment C) A single oral dose of saxagliptin 2.5-mg and metformin 500-mg tablets administered together in the fed state, followed by a 7-day (minimum) washout period. Then, (Treatment B) a single oral dose of 2.5-mg saxagliptin/500-mg metformin FDC administered in the fasted state, followed by a 7-day (minimum) washout period. Then, (Treatment D) a single oral dose of 2.5-mg saxagliptin/500-mg metformin FDC administered in the fasted state, followed by a 7-day (minimum) washout period. Then, (Treatment A) a single oral dose of saxagliptin, 2.5-mg and metformin 500-mg tablets administered together in the fasted state."}, {"id": "FG003", "title": "Treatment Schedule DCAB", "description": "(Treatment D) a single oral dose of 2.5-mg saxagliptin/500- mg metformin FDC administered in the fasted state, followed by a 7-day (minimum) washout period. Then, (Treatment C) a single oral dose of saxagliptin, 2.5-mg and metformin 500-mg tablets administered together in the fed state. Then, (Treatment A) a single oral dose of saxagliptin, 2.5-mg and metformin 500-mg tablets administered together in the fasted state, followed by a 7-day (minimum) washout period. Then, (Treatment B) a single oral dose of 2.5-mg saxagliptin/500- mg metformin FDC administered in the fasted state."}], "periods": [{"title": "Period 1: Treatment Schedule Phase 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Patient who withdrew returned for Treatment Periods 3 and 4.", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Patient withdrew; returned for period 3", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Period 2: Treatment Schedule Phase 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Period 3: Treatment Schedule Phase 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Patient who withdrew during Treatment Period 1 returned for Treatment Periods 3 and 4.", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Period 4: Treatment Schedule Phase 4", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Patient who withdrew during Treatment Period 1 returned for Treatment Periods 3 and 4.", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Treated", "description": "All participants who received study medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "27"}]}], "measures": [{"title": "Age, Customized", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "33.6", "spread": "7.42"}]}]}]}, {"title": "Age, Customized", "paramType": "MEDIAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "32", "lowerLimit": "23", "upperLimit": "49"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "13"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "14"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "8"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "19"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "22"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Observed Maximum Plasma Concentration (Cmax) of Saxagliptin, Tablets and Fixed-dose Combination (FDC), Administered to Participants in the Fasted and Fed States", "populationDescription": "All participants who received at least 1 of the 4 treatments and had sufficient plasma concentration data to facilitate the calculation of at least 1 primary pharmacokinetic parameter for at least 1 of the treatments.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "Days 1, 2, and 3 of Periods 1, 2, 3, and 4", "groups": [{"id": "OG000", "title": "Treatment A: Saxagliptin and Metformin Tablets, Fasted", "description": "A single oral dose of saxagliptin, 2.5-mg and metformin 500-mg tablets administered together in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG001", "title": "Treatment B: Saxagliptin and Metformin FDC, Fasted", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) administered in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG002", "title": "Treatment C: Saxagliptin and Metformin Tablets, Fed", "description": "A single oral dose of saxagliptin 2.5-mg and metformin 500-mg tablets administered together in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}, {"id": "OG003", "title": "Treatment D: Saxagliptin and Metformin FDC, Fed", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin FDC administered in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.54", "spread": "26"}, {"groupId": "OG001", "value": "11.53", "spread": "26"}, {"groupId": "OG002", "value": "12.71", "spread": "36"}, {"groupId": "OG003", "value": "12.79", "spread": "37"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "To demonstrate the bioequivalence of FDC tablet versus coadministration of saxagliptin and metformin tablets in the fasted and fed states, linear mixed model analyses were performed on log(Cmax), log\\[AUC(INF)\\], and log\\[AUC(0-T)\\] of saxagliptin and metformin, respectively. The factors in the model were sequence, period, and treatment as fixed effects and measurements within each subject as repeated measurements allowing for different covariance structures for the fasted and fed states.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Point estimates and 90% confidence intervals (CIs) were calculated for Treatment B to Treatment A and Treatment D to Treatment C ratios of geometric means for Cmax, AUC(INF), and AUC(0-T) of saxagliptin and metformin, respectively. Potency-corrected results were also provided. Bioequivalence will be concluded if the 90% CIs for the test-to-reference ratios of geometric means are entirely contained within 80% to 125% for both Cmax and AUC(INF). No adjustments were made for multiplicity.", "paramType": "Ratio geometric least squares (LS) mean", "paramValue": "109.53", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "102.67", "ciUpperLimit": "116.85"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "To demonstrate the bioequivalence of FDC tablet versus coadministration of saxagliptin and metformin tablets in the fasted and fed states, linear mixed model analyses were performed on log(Cmax), log\\[AUC(INF)\\], and log\\[AUC(0-T)\\] of saxagliptin and metformin, respectively. The factors in the model were sequence, period, and treatment as fixed effects and measurements within each subject as repeated measurements allowing for different covariance structures for the fasted and fed states.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Point estimates and 90% confidence intervals (CIs) were calculated for Treatment B to Treatment A and Treatment D to Treatment C ratios of geometric means for Cmax, AUC(INF), and AUC(0-T) of saxagliptin and metformin, respectively. Potency-corrected results were also provided. Bioequivalence will be concluded if the 90% CIs for the test-to-reference ratios of geometric means are entirely contained within 80% to 125% for both Cmax and AUC(INF). No adjustments were made for multiplicity.", "paramType": "Ratio geometric LS mean", "paramValue": "100.37", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "85.70", "ciUpperLimit": "117.56"}]}, {"type": "PRIMARY", "title": "Observed Cmax of Metformin, Tablets and FDC, Administered to Participants in the Fasted and Fed States", "populationDescription": "All participants who received at least 1 of the 4 treatments and had sufficient plasma concentration data to facilitate the calculation of at least 1 primary pharmacokinetic parameter for at least 1 of the treatments.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "Days 1, 2, and 3 of Periods 1, 2, 3, and 4", "groups": [{"id": "OG000", "title": "Treatment A: Saxagliptin and Metformin Tablets, Fasted", "description": "A single oral dose of saxagliptin, 2.5-mg and metformin 500-mg tablets administered together in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG001", "title": "Treatment B: Saxagliptin and Metformin FDC, Fasted", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) administered in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG002", "title": "Treatment C: Saxagliptin and Metformin Tablets, Fed", "description": "A single oral dose of saxagliptin 2.5-mg and metformin 500-mg tablets administered together in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}, {"id": "OG003", "title": "Treatment D: Saxagliptin and Metformin FDC, Fed", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin FDC administered in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1058.19", "spread": "23"}, {"groupId": "OG001", "value": "1044.70", "spread": "25"}, {"groupId": "OG002", "value": "810.08", "spread": "22"}, {"groupId": "OG003", "value": "811.94", "spread": "20"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "To demonstrate the bioequivalence of FDC tablet versus coadministration of saxagliptin and metformin tablets in the fasted and fed states, linear mixed model analyses were performed on log(Cmax), log\\[AUC(INF)\\], and log\\[AUC(0-T)\\] of saxagliptin and metformin, respectively. The factors in the model were sequence, period, and treatment as fixed effects and measurements within each subject as repeated measurements allowing for different covariance structures for the fasted and fed states", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Point estimates and 90% confidence intervals (CIs) were calculated for Treatment B to Treatment A and Treatment D to Treatment C ratios of geometric means for Cmax, AUC(INF), and AUC(0-T) of saxagliptin and metformin, respectively. Potency-corrected results were also provided. Bioequivalence will be concluded if the 90% CIs for the test-to-reference ratios of geometric means are entirely contained within 80% to 125% for both Cmax and AUC(INF). No adjustments were made for multiplicity.", "paramType": "Ratio geometric LS mean", "paramValue": "99.02", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "91.29", "ciUpperLimit": "107.41"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "To demonstrate the bioequivalence of FDC tablet versus coadministration of saxagliptin and metformin tablets in the fasted and fed states, linear mixed model analyses were performed on log(Cmax), log\\[AUC(INF)\\], and log\\[AUC(0-T)\\] of saxagliptin and metformin, respectively. The factors in the model were sequence, period, and treatment as fixed effects and measurements within each subject as repeated measurements allowing for different covariance structures for the fasted and fed states.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Point estimates and 90% confidence intervals (CIs) were calculated for Treatment B to Treatment A and Treatment D to Treatment C ratios of geometric means for Cmax, AUC(INF), and AUC(0-T) of saxagliptin and metformin, respectively. Potency-corrected results were also provided. Bioequivalence will be concluded if the 90% CIs for the test-to-reference ratios of geometric means are entirely contained within 80% to 125% for both Cmax and AUC(INF). No adjustments were made for multiplicity.", "paramType": "Ratio geometric LS mean", "paramValue": "100.21", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.86", "ciUpperLimit": "103.67"}]}, {"type": "PRIMARY", "title": "Terminal Half-life (t1/2) of Saxagliptin and Metformin, Tablets and FDC, Administered to Participants in the Fasted and Fed States", "populationDescription": "All participants who received at least 1 of the 4 treatments and had sufficient plasma concentration data to facilitate the calculation of at least 1 primary pharmacokinetic parameter for at least 1 of the treatments.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Hours", "timeFrame": "Days 1, 2, and 3 of Periods 1, 2, 3, and 4", "groups": [{"id": "OG000", "title": "Treatment A: Saxagliptin + Metformin Tablets, Fasted", "description": "A single oral dose of saxagliptin, 2.5-mg and metformin 500-mg tablets administered together in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG001", "title": "Treatment B: Saxagliptin/Metformin FDC, Fasted", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) administered in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG002", "title": "Treatment C: Saxagliptin + Metformin Tablets, Fed", "description": "A single oral dose of saxagliptin 2.5-mg and metformin 500-mg tablets administered together in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}, {"id": "OG003", "title": "Treatment D: Saxagliptin/Metformin FDC, Fed", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin FDC administered in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "25"}]}], "classes": [{"title": "t1/2 saxagliptin", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.16", "spread": "1.06"}, {"groupId": "OG001", "value": "6.69", "spread": "0.90"}, {"groupId": "OG002", "value": "5.99", "spread": "0.91"}, {"groupId": "OG003", "value": "6.15", "spread": "0.79"}]}]}, {"title": "t1/2 metformin", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.05", "spread": "3.94"}, {"groupId": "OG001", "value": "13.02", "spread": "5.37"}, {"groupId": "OG002", "value": "10.72", "spread": "2.61"}, {"groupId": "OG003", "value": "10.96", "spread": "4.03"}]}]}]}, {"type": "PRIMARY", "title": "Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUC[0-t]) for Saxagliptin, Tablets and FDC, Given in the Fasted and Fed States", "populationDescription": "All participants who received at least 1 of the 4 treatments and had sufficient plasma concentration data to facilitate the calculation of at least 1 primary pharmacokinetic parameter for at least 1 of the treatments.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng*h/mL", "timeFrame": "Days 1, 2, and 3 of Periods 1, 2, 3, and 4", "groups": [{"id": "OG000", "title": "Treatment A: Saxagliptin and Metformin Tablets, Fasted", "description": "A single oral dose of saxagliptin, 2.5-mg and metformin 500-mg tablets administered together in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG001", "title": "Treatment B: Saxagliptin and Metformin FDC, Fasted", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) administered in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG002", "title": "Treatment C: Saxagliptin and Metformin Tablets, Fed", "description": "A single oral dose of saxagliptin 2.5-mg and metformin 500-mg tablets administered together in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}, {"id": "OG003", "title": "Treatment D: Saxagliptin and Metformin FDC, Fed", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin FDC administered in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "50.28", "spread": "24"}, {"groupId": "OG001", "value": "51.60", "spread": "23"}, {"groupId": "OG002", "value": "59.00", "spread": "20"}, {"groupId": "OG003", "value": "58.94", "spread": "19"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "To demonstrate the bioequivalence of FDC tablet versus coadministration of saxagliptin and metformin tablets in the fasted and fed states, linear mixed model analyses were performed on log(Cmax), log\\[AUC(INF)\\], and log\\[AUC(0-T)\\] of saxagliptin and metformin, respectively. The factors in the model were sequence, period, and treatment as fixed effects and measurements within each subject as repeated measurements allowing for different covariance structures for the fasted and fed states.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Point estimates and 90% confidence intervals (CIs) were calculated for Treatment B to Treatment A and Treatment D to Treatment C ratios of geometric means for Cmax, AUC(INF), and AUC(0-T) of saxagliptin and metformin, respectively. Potency-corrected results were also provided. Bioequivalence will be concluded if the 90% CIs for the test-to-reference ratios of geometric means are entirely contained within 80% to 125% for both Cmax and AUC(INF). No adjustments were made for multiplicity.", "paramType": "Ratio geometric LS mean", "paramValue": "102.34", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "97.96", "ciUpperLimit": "106.91"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "To demonstrate the bioequivalence of FDC tablet versus coadministration of saxagliptin and metformin tablets in the fasted and fed states, linear mixed model analyses were performed on log(Cmax), log\\[AUC(INF)\\], and log\\[AUC(0-T)\\] of saxagliptin and metformin, respectively. The factors in the model were sequence, period, and treatment as fixed effects and measurements within each subject as repeated measurements allowing for different covariance structures for the fasted and fed states.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Point estimates and 90% confidence intervals (CIs) were calculated for Treatment B to Treatment A and Treatment D to Treatment C ratios of geometric means for Cmax, AUC(INF), and AUC(0-T) of saxagliptin and metformin, respectively. Potency-corrected results were also provided. Bioequivalence will be concluded if the 90% CIs for the test-to-reference ratios of geometric means are entirely contained within 80% to 125% for both Cmax and AUC(INF). No adjustments were made for multiplicity.", "paramType": "Ratio geometric LS mean", "paramValue": "99.78", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.61", "ciUpperLimit": "103.05"}]}, {"type": "SECONDARY", "title": "Number of Participants With Death as Outcome, Serious Adverse Events, and Adverse Events (AEs) Leading to Discontinuation", "description": "An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.", "populationDescription": "All enrolled participants who received study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Continuously over Days 1 to 3 of treatment Periods 1, 2, 3, and 4", "groups": [{"id": "OG000", "title": "Treatment A: Saxagliptin + Metformin Tablets, Fasted", "description": "A single oral dose of saxagliptin, 2.5-mg and metformin 500-mg tablets administered together in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG001", "title": "Treatment B: Saxagliptin/Metformin FDC, Fasted", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) administered in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG002", "title": "Treatment C: Saxagliptin + Metformin Tablets, Fed", "description": "A single oral dose of saxagliptin 2.5-mg and metformin 500-mg tablets administered together in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}, {"id": "OG003", "title": "Treatment D: Saxagliptin/Metformin FDC, Fed", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin FDC administered in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "26"}]}], "classes": [{"title": "Death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Serious Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "AEs Leading to Discontinuation", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Clinically Significant Abnormalities in Hematology, Serum Chemistry, and Urinalysis Laboratory Test Results", "description": "Clinically significant was determined by the investigator. Hematology tests included hemoglobin, hematocrit, red blood cell count, total leukocyte count (including differential), and platelet count. Serum chemistry tests included aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, lactate dehydrogenase, creatinine, blood urea nitrogen, uric acid, fasting glucose, total protein, albumin, sodium, potassium, chloride, calcium, phosphorus, and creatine kinase. Urinalysis included protein, glucose, blood, leukocyte esterase, specific gravity, and pH.", "populationDescription": "All enrolled participants who received study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "At screening visit, at Day -1 of Periods 1 through 4, and at discharge", "groups": [{"id": "OG000", "title": "Treatment A: Saxagliptin + Metformin Tablets, Fasted", "description": "A single oral dose of saxagliptin, 2.5-mg and metformin 500-mg tablets administered together in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG001", "title": "Treatment B: Saxagliptin/Metformin FDC, Fasted", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) administered in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG002", "title": "Treatment C: Saxagliptin + Metformin Tablets, Fed", "description": "A single oral dose of saxagliptin 2.5-mg and metformin 500-mg tablets administered together in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}, {"id": "OG003", "title": "Treatment D: Saxagliptin/Metformin FDC, Fed", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin FDC administered in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "26"}]}], "classes": [{"title": "Hematology test results", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Serum chemistry test results", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Urinalysis results", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Results", "description": "Clinically significant was determined by the investigator. ECGs were recorded after participants had been supine for at least 5 minutes.", "populationDescription": "All enrolled participants who received study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "At screening visit, Day -1 of Period 1, and at study discharge", "groups": [{"id": "OG000", "title": "Treatment A: Saxagliptin + Metformin Tablets, Fasted", "description": "A single oral dose of saxagliptin, 2.5-mg and metformin 500-mg tablets administered together in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG001", "title": "Treatment B: Saxagliptin/Metformin FDC, Fasted", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) administered in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG002", "title": "Treatment C: Saxagliptin + Metformin Tablets, Fed", "description": "A single oral dose of saxagliptin 2.5-mg and metformin 500-mg tablets administered together in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}, {"id": "OG003", "title": "Treatment D: Saxagliptin/Metformin FDC, Fed", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin FDC administered in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Clinically Significant Abnormalities in Body Temperature, Blood Pressure, or Heart Rate", "description": "Clinically significant was determined by the investigator. Blood pressure and heart rate were measured after the participant had been seated quietly for at least 5 minutes.", "populationDescription": "All enrolled participants who received study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "At screening visit, prior to dosing on Day 1 of Periods 1 through 4, and at study discharge.", "groups": [{"id": "OG000", "title": "Treatment A: Saxagliptin + Metformin Tablets, Fasted", "description": "A single oral dose of saxagliptin, 2.5-mg and metformin 500-mg tablets administered together in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG001", "title": "Treatment B: Saxagliptin/Metformin FDC, Fasted", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) administered in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG002", "title": "Treatment C: Saxagliptin + Metformin Tablets, Fed", "description": "A single oral dose of saxagliptin 2.5-mg and metformin 500-mg tablets administered together in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}, {"id": "OG003", "title": "Treatment D: Saxagliptin/Metformin FDC, Fed", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin FDC administered in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "AUC[0-t] for Metformin, Tablets and FDC, Given in the Fasted and Fed States", "populationDescription": "All participants who received at least 1 of the 4 treatments and had sufficient plasma concentration data to facilitate the calculation of at least 1 primary pharmacokinetic parameter for at least 1 of the treatments.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng*h/mL", "timeFrame": "Days 1, 2, and 3 of Periods 1, 2, 3, and 4", "groups": [{"id": "OG000", "title": "Treatment A: Saxagliptin and Metformin Tablets, Fasted", "description": "A single oral dose of saxagliptin, 2.5-mg and metformin 500-mg tablets administered together in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG001", "title": "Treatment B: Saxagliptin and Metformin FDC, Fasted", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) administered in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG002", "title": "Treatment C: Saxagliptin and Metformin Tablets, Fed", "description": "A single oral dose of saxagliptin 2.5-mg and metformin 500-mg tablets administered together in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}, {"id": "OG003", "title": "Treatment D: Saxagliptin and Metformin FDC, Fed", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin FDC administered in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8035.25", "spread": "22"}, {"groupId": "OG001", "value": "7906.00", "spread": "21"}, {"groupId": "OG002", "value": "7497.56", "spread": "23"}, {"groupId": "OG003", "value": "7654.00", "spread": "19"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "To demonstrate the bioequivalence of FDC tablet versus coadministration of saxagliptin and metformin tablets in the fasted and fed states, linear mixed model analyses were performed on log(Cmax), log\\[AUC(INF)\\], and log\\[AUC(0-T)\\] of saxagliptin and metformin, respectively. The factors in the model were sequence, period, and treatment as fixed effects and measurements within each subject as repeated measurements allowing for different covariance structures for the fasted and fed states.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Point estimates and 90% confidence intervals (CIs) were calculated for Treatment B to Treatment A and Treatment D to Treatment C ratios of geometric means for Cmax, AUC(INF), and AUC(0-T) of saxagliptin and metformin, respectively. Potency-corrected results were also provided. Bioequivalence will be concluded if the 90% CIs for the test-to-reference ratios of geometric means are entirely contained within 80% to 125% for both Cmax and AUC(INF). No adjustments were made for multiplicity.", "paramType": "Ratio geometric LS mean", "paramValue": "102.34", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "97.96", "ciUpperLimit": "106.91"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "To demonstrate the bioequivalence of FDC tablet versus coadministration of saxagliptin and metformin tablets in the fasted and fed states, linear mixed model analyses were performed on log(Cmax), log\\[AUC(INF)\\], and log\\[AUC(0-T)\\] of saxagliptin and metformin, respectively. The factors in the model were sequence, period, and treatment as fixed effects and measurements within each subject as repeated measurements allowing for different covariance structures for the fasted and fed states.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Point estimates and 90% confidence intervals (CIs) were calculated for Treatment B to Treatment A and Treatment D to Treatment C ratios of geometric means for Cmax, AUC(INF), and AUC(0-T) of saxagliptin and metformin, respectively. Potency-corrected results were also provided. Bioequivalence will be concluded if the 90% CIs for the test-to-reference ratios of geometric means are entirely contained within 80% to 125% for both Cmax and AUC(INF). No adjustments were made for multiplicity.", "paramType": "Ratio geometric LS mean", "paramValue": "101.82", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.10", "ciUpperLimit": "107.88"}]}, {"type": "PRIMARY", "title": "AUC From Time 0 Extrapolated to Infinity (AUC[0-inf]) for Saxagliptin, Tablets and FDC, Given in the Fasted and Fed States", "populationDescription": "All participants who received at least 1 of the 4 treatments and had sufficient plasma concentration data to facilitate the calculation of at least 1 primary pharmacokinetic parameter for at least 1 of the treatments.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng*h/mL", "timeFrame": "Days 1, 2, and 3 of Periods 1, 2, 3, and 4", "groups": [{"id": "OG000", "title": "Treatment A: Saxagliptin + Metformin Tablets, Fasted", "description": "A single oral dose of saxagliptin, 2.5-mg and metformin 500-mg tablets administered together in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG001", "title": "Treatment B: Saxagliptin/Metformin FDC, Fasted", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) administered in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG002", "title": "Treatment C: Saxagliptin + Metformin Tablets, Fed", "description": "A single oral dose of saxagliptin 2.5-mg and metformin 500-mg tablets administered together in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}, {"id": "OG003", "title": "Treatment D: Saxagliptin/Metformin FDC, Fed", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin FDC administered in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "25"}, {"groupId": "OG003", "value": "25"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "52.17", "spread": "24"}, {"groupId": "OG001", "value": "53.73", "spread": "23"}, {"groupId": "OG002", "value": "61.31", "spread": "20"}, {"groupId": "OG003", "value": "60.88", "spread": "20"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "To demonstrate the bioequivalence of FDC tablet versus coadministration of saxagliptin and metformin tablets in the fasted and fed states, linear mixed model analyses were performed on log(Cmax), log\\[AUC(INF)\\], and log\\[AUC(0-T)\\] of saxagliptin and metformin, respectively. The factors in the model were sequence, period, and treatment as fixed effects and measurements within each subject as repeated measurements allowing for different covariance structures for the fasted and fed states.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Point estimates and 90% confidence intervals (CIs) were calculated for Treatment B to Treatment A and Treatment D to Treatment C ratios of geometric means for Cmax, AUC(INF), and AUC(0-T) of saxagliptin and metformin, respectively. Potency-corrected results were also provided. Bioequivalence will be concluded if the 90% CIs for the test-to-reference ratios of geometric means are entirely contained within 80% to 125% for both Cmax and AUC(INF). No adjustments were made for multiplicity.", "paramType": "Ratio (%) of geometric LS mean", "paramValue": "102.64", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "98.31", "ciUpperLimit": "107.16"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "To demonstrate the bioequivalence of FDC tablet versus coadministration of saxagliptin and metformin tablets in the fasted and fed states, linear mixed model analyses were performed on log(Cmax), log\\[AUC(INF)\\], and log\\[AUC(0-T)\\] of saxagliptin and metformin, respectively. The factors in the model were sequence, period, and treatment as fixed effects and measurements within each subject as repeated measurements allowing for different covariance structures for the fasted and fed states.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Point estimates and 90% confidence intervals (CIs) were calculated for Treatment B to Treatment A and Treatment D to Treatment C ratios of geometric means for Cmax, AUC(INF), and AUC(0-T) of saxagliptin and metformin, respectively. Potency-corrected results were also provided. Bioequivalence will be concluded if the 90% CIs for the test-to-reference ratios of geometric means are entirely contained within 80% to 125% for both Cmax and AUC(INF). No adjustments were made for multiplicity.", "paramType": "Ratio (%) of geometric LS mean", "paramValue": "99.22", "ciPctValue": "90", "ciLowerLimit": "96.48", "ciUpperLimit": "102.04"}]}, {"type": "PRIMARY", "title": "AUC[0-inf] for Metformin, Tablets and FDC, Administered in the Fasted and Fed States", "populationDescription": "All participants who received at least 1 of the 4 treatments and had sufficient plasma concentration data to facilitate the calculation of at least 1 primary pharmacokinetic parameter for at least 1 of the treatments.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng*h/mL", "timeFrame": "Days 1, 2, and 3 of Periods 1, 2, 3, and 4", "groups": [{"id": "OG000", "title": "Treatment A: Saxagliptin + Metformin Tablets, Fasted", "description": "A single oral dose of saxagliptin, 2.5-mg and metformin 500-mg tablets administered together in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG001", "title": "Treatment B: Saxagliptin/Metformin FDC, Fasted", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) administered in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG002", "title": "Treatment C: Saxagliptin + Metformin Tablets, Fed", "description": "A single oral dose of saxagliptin 2.5-mg and metformin 500-mg tablets administered together in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}, {"id": "OG003", "title": "Treatment D: Saxagliptin/Metformin FDC, Fed", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin FDC administered in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "25"}, {"groupId": "OG003", "value": "25"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8142.68", "spread": "22"}, {"groupId": "OG001", "value": "8070.25", "spread": "20"}, {"groupId": "OG002", "value": "7612.94", "spread": "24"}, {"groupId": "OG003", "value": "7690.69", "spread": "18"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "To demonstrate the bioequivalence of FDC tablet versus coadministration of saxagliptin and metformin tablets in the fasted and fed states, linear mixed model analyses were performed on log(Cmax), log\\[AUC(INF)\\], and log\\[AUC(0-T)\\] of saxagliptin and metformin, respectively. The factors in the model were sequence, period, and treatment as fixed effects and measurements within each subject as repeated measurements allowing for different covariance structures for the fasted and fed states.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Point estimates and 90% confidence intervals (CIs) were calculated for Treatment B to Treatment A and Treatment D to Treatment C ratios of geometric means for Cmax, AUC(INF), and AUC(0-T) of saxagliptin and metformin, respectively. Potency-corrected results were also provided. Bioequivalence will be concluded if the 90% CIs for the test-to-reference ratios of geometric means are entirely contained within 80% to 125% for both Cmax and AUC(INF). No adjustments were made for multiplicity.", "paramType": "Ratio geometric LS mean", "paramValue": "99.04", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "92.90", "ciUpperLimit": "105.59"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "To demonstrate the bioequivalence of FDC tablet versus coadministration of saxagliptin and metformin tablets in the fasted and fed states, linear mixed model analyses were performed on log(Cmax), log\\[AUC(INF)\\], and log\\[AUC(0-T)\\] of saxagliptin and metformin, respectively. The factors in the model were sequence, period, and treatment as fixed effects and measurements within each subject as repeated measurements allowing for different covariance structures for the fasted and fed states.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Point estimates and 90% confidence intervals (CIs) were calculated for Treatment B to Treatment A and Treatment D to Treatment C ratios of geometric means for Cmax, AUC(INF), and AUC(0-T) of saxagliptin and metformin, respectively. Potency-corrected results were also provided. Bioequivalence will be concluded if the 90% CIs for the test-to-reference ratios of geometric means are entirely contained within 80% to 125% for both Cmax and AUC(INF). No adjustments were made for multiplicity.", "paramType": "Ratio geometric LS mean", "paramValue": "102.77", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.82", "ciUpperLimit": "109.09"}]}, {"type": "PRIMARY", "title": "Time to Achieve the Observed Maximum Plasma Concentration (Tmax) for Saxagliptin and Metformin, Tablets and FDC, Administered to Participants in the Fasted and Fed States", "populationDescription": "All participants who received at least 1 of the 4 treatments and had sufficient plasma concentration data to facilitate the calculation of at least 1 primary pharmacokinetic parameter for at least 1 of the treatments.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Hours", "timeFrame": "Days 1, 2, and 3 of Periods 1, 2, 3, and 4", "groups": [{"id": "OG000", "title": "Treatment A: Saxagliptin + Metformin Tablets, Fasted", "description": "A single oral dose of saxagliptin, 2.5-mg and metformin 500-mg tablets administered together in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG001", "title": "Treatment B: Saxagliptin/Metformin FDC, Fasted", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) administered in the fasted state, followed by a 7-day (minimum) washout period."}, {"id": "OG002", "title": "Treatment C: Saxagliptin + Metformin Tablets, Fed", "description": "A single oral dose of saxagliptin 2.5-mg and metformin 500-mg tablets administered together in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}, {"id": "OG003", "title": "Treatment D: Saxagliptin/Metformin FDC, Fed", "description": "A single oral dose of 2.5-mg saxagliptin/500-mg metformin FDC administered in the morning within 5 minutes of completing a standard high-fat, high-calorie breakfast (fed state), followed by a 7-day (minimum) washout period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "26"}]}], "classes": [{"title": "Tmax saxagliptin", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.00", "lowerLimit": "0.25", "upperLimit": "3.00"}, {"groupId": "OG001", "value": "0.75", "lowerLimit": "0.30", "upperLimit": "4.00"}, {"groupId": "OG002", "value": "1.50", "lowerLimit": "0.50", "upperLimit": "8.00"}, {"groupId": "OG003", "value": "1.00", "lowerLimit": "0.50", "upperLimit": "3.00"}]}]}, {"title": "Tmax metformin", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.00", "lowerLimit": "0.50", "upperLimit": "4.00"}, {"groupId": "OG001", "value": "3.00", "lowerLimit": "1.00", "upperLimit": "6.00"}, {"groupId": "OG002", "value": "4.00", "lowerLimit": "2.00", "upperLimit": "6.00"}, {"groupId": "OG003", "value": "4.00", "lowerLimit": "1.50", "upperLimit": "8.00"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Fasted: 2.5mg Onglyza + 500mg Glucophage", "seriousNumAffected": 0, "seriousNumAtRisk": 27, "otherNumAffected": 2, "otherNumAtRisk": 27}, {"id": "EG001", "title": "Fasted: 2.5mg Saxa/500mg Metformin FDC", "seriousNumAffected": 0, "seriousNumAtRisk": 26, "otherNumAffected": 1, "otherNumAtRisk": 26}, {"id": "EG002", "title": "Fed: 2.5mg Onglyza + 500mg Glucophage", "seriousNumAffected": 0, "seriousNumAtRisk": 26, "otherNumAffected": 7, "otherNumAtRisk": 26}, {"id": "EG003", "title": "Fed: 2.5mg Saxa/500mg Metformin FDC", "seriousNumAffected": 0, "seriousNumAtRisk": 26, "otherNumAffected": 4, "otherNumAtRisk": 26}], "otherEvents": [{"term": "Asthenopia", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Abnormal dreams", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 26}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 26}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 26}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}]}, {"term": "Eructation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}]}, {"term": "Flatulence", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Abdominal distension", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}]}, {"term": "Bowel movement irregularity", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Hidradenitis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 26}]}, {"term": "Vessel puncture site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}]}, {"term": "Venipuncture site inflammation", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 26}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \u226460 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."}, "pointOfContact": {"title": "Boaz Hirschberg", "organization": "AstraZeneca Pharmaceuticals", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}